Adenocarcinoma — Research

Adenocarcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	490,877	`("Adenocarcinoma"[mh] OR "Adenocarcinomas"[mh] OR "Adenoma, Malignant"[mh] OR "Adenomas, Malignant"[mh])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	93,894	`("Adenocarcinoma"[mh] OR "Adenocarcinomas"[mh] OR "Adenoma, Malignant"[mh] OR "Adenomas, Malignant"[mh]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	15,455	`("Adenocarcinoma"[mh] OR "Adenocarcinomas"[mh] OR "Adenoma, Malignant"[mh] OR "Adenomas, Malignant"[mh]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 20 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (378)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 26–50 of 378 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
· J Clin Oncol · 2013 · PMID 23816960 · validated civic_curation pubmed
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
· Lancet Oncol · 2014 · PMID 24439929 · validated civic_curation pubmed
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
· Lancet Oncol · 2015 · PMID 25589191 · validated civic_curation pubmed